Oral lesions as clinical markers of highly active antiretroviral therapy failure: A nested case-control study in Mexico City

Clinical Infectious Diseases

Volumn 45, Issue 7, 2007, Pages 925-932

  Ramírez Amador, Velia ^a   Ponce de León, Sergio ^b   Anaya Saavedra, Gabriela ^a   Ramírez, Brenda Crabtree ^b   Sierra Madero, Juan ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOUTH EXAMINATION; MOUTH LESION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RISK; THRUSH; TREATMENT FAILURE; VIRUS LOAD; AIDS RELATED COMPLEX; DISEASE COURSE; MEXICO; MIDDLE AGED; MOUTH DISEASE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, ORAL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEXICO; MIDDLE AGED; MOUTH DISEASES; ODDS RATIO; TREATMENT FAILURE; VIRAL LOAD;

EID: 34848830118     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521251     Document Type: Article

References (36)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
2. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 27 February 2007.
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827-43.
4. Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 2006; 19:57-62.
5. Kerdpon D, Pongsiriwet S, Pangsomboon K, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Dis 2004; 10:138-44.
6. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 2005; 83:700-6.
7. + lymphocytes and viral load before the onset of oral candidosis and hairy leukoplakia in a cohort of Mexican HIV-infected patients. AIDS Res Hum Retroviruses 2005; 21:981-90.
8. Greenspan D, Gange SJ, Phelan JA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 2004; 83:145-50.
9. Campo J, Del Romero J, Castilla J, García S, Rodríguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002; 31:5-10.
10. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, et al. Oral clinical markers and viral load in a prospective cohort of Mexican HIV-infected patients. AIDS 2001; 15:1910-1.
11. Patton LL, McKaig RG, Eron Jr JJ, Lawrence HP, Strauss RP. Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. AIDS 1999; 13:2174-6.
12. EC-Clearinghouse on Oral Problems Related to HIV Infection and World Health Organization Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22:289-91.
13. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L. Markers of immunodeficiency and mechanism of HAART therapy on oral lesions. Adv Dent Res 2006; 19:146-51.
14. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med 2004; 5:50-4.
15. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S. The changing clinical spectrum of human immunodeficiency virus (HIV) - related oral lesions in 1,000 consecutive patients: a twelve-year study in a referral center in Mexico. Medicine 2003; 82:39-50.
16. Skolasky Rl, Phair J, Detels R, Riddler S, Margolick J, Jacobson LP. Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17:1311-6.
17. Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannanta SW, Axell TE. Prognostic significance of HIV-associated oral lesions and their relation with therapy. Oral Dis 2002; 8:110-4.
18. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002; 8:34-9.
19. Greenspan JS. Sentinels and signposts: the epidemiology and significance of the oral manifestations of HIV disease. Oral Dis 1997; 3(Suppl 1):S13-7.
20. Miziara ID, Weber R. Oral candidosis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients. Oral Dis 2006; 12:402-7.
21. Patton LL. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:182-8.
22. Gaitán-Cepeda LA, Martinez-Gonzalez M, Ceballos-Salobreña A. Oral candidosis as clinical marker of immune failure in patients with HIV/AIDS on HAART. AIDS Patient Care STDS 2005; 19:70-7.
23. Tappuni AR, Fleming GJP. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:623-8.
24. Diz Dios P, Ocampo A, Miralles C, Limeres J, Tomás I. Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:403-4.
25. Etminan N. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004; 24:1105-9.
26. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Designing clinical research. 2nd ed. Philadelphia: Lippincott Williams & Williams, 2001:99-100.
27. Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia: WB Saunders Company; 1985:533-60.
28. Mercante DE, Leigh JE, Lilly EA, McNulty K, Fidel PL. Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 42:578-83.
29. Ohmit SE, Sobel JD, Schuman P, et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunideficiency virus (HIV) - seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:118-27.
30. Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien H-C, Patton LL. Incidence of oral candidosis and oral hairy leukoplakia in HIV-infected adults in North Carolina. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99:39-47.
31. Chattopadhyay A, Caplan DJ, Slade DG, Shugars DC, Tien HC, Patton LL. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent Oral Epidemiol 2005; 33:35-44.
32. Greenspan D, Komaroff E, Redford M, et al. Oral mucosal lesions and HIV viral load in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr 2000; 25:44-50.
33. Margiotta V, Campisi G, Mancuso S. Plasma HIV-1 RNA and route of transmission in oral candidiasis and oral hairy leukoplakia. Oral Dis 2000; 6:194-5.
34. + cell count and viral load in an Italian study population. J Oral Pathol Med 1999; 28:173-7.
35. Moura MD, Grossmann S de M, Fonseca LM, Senna MI, Mesquita RA. Risk factors for oral hairy leukoplakia in HIV-infected adults of Brazil. J Oral Pathol Med 2006; 35:321-6.
36. + cell count, and HIV-1 plasma viral load. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:448-54.